Management Team
Hilde H Steineger
CEO employed since 2025, born 1966. 0 shares and 1 000 000 options
Hilde H Steineger has extensive executive and board-level experience within the life science sector, spanning financial analysis, venture capital, business development, and top management roles. Steineger was previously CEO of Staten Biotechnology as well as COO and co-founder of NorthSea Therapeutics.
Earlier positions include Head of Strategic Innovation Management in the Nutrition and Health Division at BASF, as well as Head of Global Omega-3 Innovation Management—covering R&D, medical affairs, and business development functions. She has broad financial background as a financial analyst in Nordea Securities and venture capitalist in NeoMed Management as well as board experience in both listed and private biotech enterprises, including Algeta ASA (acquired by Bayer AG), OncoInvent, and Strongbridge Biopharma plc. Steineger holds a PhD in medical biochemistry (University of Oslo, 2000) and MSc in molecular biology/biotechnology (1992).
David Liberg
CSO employed since 2015, born 1969. Holdings: 69 087 shares and 630 000 options
David Liberg graduated with a PhD in 2001 and has over twentyfive years of research experience within immunology and tumour biology. Liberg has worked within the pharmaceutical industry for the last eighteen years, with responsibility for early research projects and activities in tumour immunology. He has extensive experience of pre-clinical phase cancer projects. His most recent position was at Active Biotech AB, where he worked as Project Manager Drug Development as well as Head of Cell Biology and Biochemistry. Liberg has also carried out research at Imperial College in the UK and at Lund University.
Patrik Renblad
CFO employed since 2023, born 1970. Holdings: 141 405 shares and 600 000 options
Patrik Renblad holds a MSc in Business Administration and Economics from Lund University. He has more than 20 years of experience from the Life Science industry. With a strong financial background and focus, he has served in various roles across the pharmaceutical value chain and across geographies for AstraZeneca, LEO Pharma and SynAct Pharma. Prior to joining Cantargia, Renblad led SynAct Pharmas listing on Nasdaq Stockholm in 2022 as CFO. Before that, he served 10 years at LEO Pharma, amongst his roles were head of Research & Development Finance unit and local CFO for the Chinese affiliate in Shanghai.
Ton Berkien
CBO employed since 2024, born 1968. Holdings: 53 423 shares and 450 000 options
Ton Berkien holds a BA degree in economics/business information from Saxion University of Applied Sciences in the Netherlands, as well as an LSid from SIMI and from PwC/Harvard Business School/IMD. He has more than 20 years of experience in the Life Science Industry. Berkien has previously held senior business development positions at Amgen, Nuevolution, Takeda and Nycomed. Before that he held positions at Ferring Pharmaceuticals, PwC, KPMG and Gilde Investment Management. Further, he is Chairman of the Board in Gedea Biotech AB and board member in Adjutec Pharma A/S.
Wolfram Dempke
CMO employed since 2025, born 1962. Holdings: 0 shares and 0 options
Professor Wolfram Dempke, MD, PhD, MBA (board-certified in haematology and oncology) is a global leader with a distinguished 35-year career in oncology, haematology, and academia with significant contributions in clinical developments in ovarian, lung and pancreatic cancers, and leukaemias and lymphomas. This included the development of phase 1/2 trials for an anti-CD123 antibody in AML, first-in-human studies with novel immune-oncology drugs (immune checkpoint antibodies), development of new EGFR-targeted agents and the development of novel non-cardiotoxic anthracyclines in AMLs and sarcomas. In addition, he provided support for the EMA and FDA submission of mogamulizumab, dasatinib, ipilimumab, capmatinib, gefitinib and osimertinib based on the phase 2/3 trial results.
Dempke is a full professor of haematology and oncology at Munich University Medical School and has authored and co-authored over 150 peer-reviewed papers and abstracts (including 5 textbooks). He is still seeing patients on a regular basis, mainly lung cancer, pancreatic cancer, and leukaemias and is a senior lecturer at Munich University, Campus Grosshadern. In addition, Wolfram holds an MBA in international financing (venture capital, financial analyses, investor engagement).
